氟维司群联合曲妥珠单抗对人乳腺癌BT-474细胞株协同作用研究

Research on the effectiveness of fulvestrant combined with trastuzumab on the human breast cancer cell line BT-474

目的探讨氟维司群联合曲妥珠单抗对人乳腺癌BT-474细胞株的作用。方法 WST-1、Annexin/PI法分别测氟维司群、曲妥珠单抗单独与联合对BT-474细胞株增殖抑制率及凋亡率,Western blot法测药物对p-Akt、p-MAPK蛋白表达影响。结果各组对BT-474细胞增殖抑制作用有浓度依赖性,CIED50=0.466,联合组较单药组凋亡率增高(P<0.05),氟维司群组p-Akt、p-MAPK蛋白表达增高,联合组较氟维司群组明显降低。结论氟维司群联合曲妥珠单抗对BT-474细胞作用协同,可能与增强抑制细胞增殖、促进细胞凋亡及抑制氟维司群增高p-Akt、p-MAPK蛋白表达有关。

Objective To investigate the effectiveness of fulvestrant combined with trastuzumab on the human breastcancer cell line BT-474.Methods Inhibition of BT-474 cell proliferation at different concentrations of fulvestrant,trastuzumab and the two drugs combined was assessed using the WST-1 assay.Flow cytometry（FCM） was used to detectthe cell apoptosis rates by Annexin-V/PI assay. Moreover,the effect fulvestrant and trastuzumab respectively andcombinedly have on the proteins p-Akt and p-MAPK was detected by Western blot assay.Results The cellproliferation was increasingly inhibited by fulvestrant,trastuzumab or them combined when each group’s drugconcentration added,with a CIED50 of 0.466.When fulvestrant and trastuzumab combined,the cell apoptosis rates weredistinctly increased（P〈0.05）.Furthermore,the level of proteins p-Akt and p-MAPK expressed in the cell BT-474 wasraised by fulvestrant,but definitively reduced when fulvestrant combined with trastuzumab.Conclusion Fulvestrantsynergizes trastuzumab if they combine when acing on the cell line BT-474,maybe because fulvestrant combined withtrastuzumab increases the cell proliferation inhibition,promotes the cell apoptosis and restrains fulvestrant fromenhancing the proteins p-Akt and p-MAPK expression.